CCM
UTHR icon

Credo Capital Management’s United Therapeutics UTHR Stock Holding History

Credo Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		$22K Hold
193
– – 0.09% 115
2013
Q3 		$15K Buy
+193
New +$14.1K 0.03% 144

Other funds holding UTHR

BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
AL
AJO LP Philadelphia, Pennsylvania $199M AUM 109.68% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
HCM
Herndon Capital Management Atlanta, Georgia $659M AUM 22.02% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Credo Capital Management's UTHR Position: Q4 2013 in Review

Credo Capital Management held its United Therapeutics (UTHR) position steady in Q4 2013 at 193 shares worth $22K. The position accounts for 0.09% of the portfolio, ranked #115.

Credo Capital Management first reported a position in UTHR in Q3 2013 and has held it in 2 quarters since. 321 funds tracked by Wall St. Rank hold UTHR as of Q4 2013.

  • Credo Capital Management held 193 shares of United Therapeutics worth $22K as of Q4 2013.
  • Credo Capital Management left its United Therapeutics share count unchanged in Q4 2013.
  • United Therapeutics made up 0.09% of Credo Capital Management's portfolio in Q4 2013, its #115 holding.
  • Credo Capital Management first reported a position in United Therapeutics in Q3 2013 and has held it in 2 quarters since.
  • 321 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2013.

Based on Credo Capital Management's 13F filing for Q4 2013, filed 24 Jan 2014.